FDA Brief

Warning letters Drugs

FDA warning letter to

Stream2Sea, LLC

MediumIssued Feb 2Posted Sep 29Center for Drug Evaluation and Research (CDER)

FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

What happened

FDA inspected Stream2Sea's drug manufacturing facility in Bowling Green, FL, from July 9 to 15, 2025. Investigators found the firm released OTC drug batches without testing the finished product for identity, strength, quality or purity, and one batch was released before the quality unit documented release approval. FDA also found no identity testing of incoming raw materials including active ingredients, reliance on supplier certificates of analysis without qualifying suppliers, and cleaning of shared drug and cosmetics equipment that was neither validated nor properly documented.

What FDA found

  1. The firm did not test each finished drug batch for identity and strength of active ingredients, or for other quality attributes, before releasing it.

    21 CFR 211.165(a)
  2. The firm did not test incoming raw materials and components, including active ingredients, to confirm their identity, and did not qualify suppliers or verify that supplier test results were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm did not validate its cleaning procedures to remove drug residue and cleaning agents or control microbes on equipment shared between OTC drugs and cosmetics, and did not document what cleaning was done.

    21 CFR 211.67(b)

What FDA wants

FDA tells the firm to fix the violations promptly and to respond in writing within 15 working days with corrective actions, or explain any delay and give a completion schedule. The letter also asks for independent reviews of the laboratory, material and cleaning systems, and strongly recommends hiring a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drug products from this contract manufacturer
  • companies sharing drug and cosmetic manufacturing equipment
  • quality teams that rely on supplier certificates of analysis instead of identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk